Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
At median 30.6 months follow up, results show that pembrolizumab+axitinib continues to have superior survival outcomes vs sunitinib (overall survival: median not reached vs 35.7 months; HR 0.68; p=0.0003; progression-free survival: median 15.4 vs 11.1 months; 0.71, p<0.0001).
Source:
The Lancet Oncology